Written by Dr. Chepsy Philip from Believers Church Medical College Hospital, Tiruvalla, Kerala, India KEYNOTE-087 is a multicentre, single-arm, multicohort, nonrandomized, phase 2 study of pembrolizumab in patients with R/R cHL who
Author: Dr. Arya Mariam Roy from Roswell Park Comprehensive Cancer Center What are antibody drug conjugates (ADCs)? Antibody drug conjugates (ADCs) are newer targeted medicines that are specifically designed to deliver chemotherapy agents
More
Bellevue, WA – October 24, 2024 The Binaytara Foundation, a leading global cancer non-profit organization dedicated to improving access to cancer care, is set to host its annual Global Oncology Summit on
More
ESMO 2023 Update – KEYNOTE-671: The First Perioperative Immunotherapy Clinical Trial in Non-Small Cell Lung Cancer Improving Overall Survival Author: Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic, Head & Neck Medical Oncology
More
ESMO 2023 Update – MARIPOSA: Amivantamab + Lazertinib Improves Progression-Free Survival Compared to Osimertinib in EGFR-Mutated, Treatment-Naïve Non-Small Cell Lung Cancer Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic, Head & Neck
More
ESMO 2023 Update – ALINA: Adjuvant Alectinib Improves Disease-Free Survival in Resected Early-Stage Non-Small Cell Lung Cancer Author: Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic, Head & Neck Medical Oncology University of
More
LIBRETTO-431: Randomized phase III study of selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive advanced NSCLC Author: Dr. Anam Kamal Selpercatinib is a brain penetrant, a highly selective and potent inhibitor of RET signaling that
More
ESMO 2023 Update – CheckMate 77T: Another Phase 3 Trial of Perioperative Immunotherapy Improving Event-Free Survival for Resectable Stage II-III Non-Small Cell Lung Cancer Author: Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic,
More
We are excited to bring the conference coverage/highlights from the highly anticipated “2023 Precision Oncology Summit” that is taking place this weekend in the vibrant city of San Francisco. This important event
More
On August 28, 2023, the U.S. Food and Drug Administration approved luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) without prior erythropoiesis-stimulating agent (ESA) use,
More
Written by Dr. Chepsy Philip from Believers Church Medical College Hospital, Tiruvalla, Kerala, India KEYNOTE-087 is a multicentre, single-arm, multicohort, nonrandomized, phase 2 study of pembrolizumab in patients with R/R cHL who
More